Results 21 to 30 of about 7,128 (244)

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Haematologica, 2017
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov   +10 more
doaj   +1 more source

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2022
The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh, Mattias A.S. Henning, Gregor B.E. Jemec, Kristina S. Ibler   +3 more
doaj   +1 more source

Janus kinase inhibitors: between prescription authorization and reimbursability

Reumatismo, 2023
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli, F. Conti, R. Caporali, F. Iannone, F. Cacciapaglia, on behalf of the Steering Committee of the Italian Society of Rheumatology   +5 more
doaj   +1 more source

The Emerging World of JAK Inhibitors

Nepal Journal of Dermatology, Venereology & Leprology
The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj   +3 more sources

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Haematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi   +13 more
doaj   +1 more source

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

BMC Infectious Diseases, 2021
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz, Avi J. Cohen, Andre P. Rebaza, James Vanchieri, Martin D. Slade, Charles S. Dela Cruz, Lokesh Sharma   +6 more
doaj   +1 more source

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +1 more source

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders

Pharmacological Research, 2022
The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj   +1 more source

Structural basis of Janus kinase trans-activation

Cell Reports, 2023
Summary: Janus kinases (JAKs) mediate signal transduction downstream of cytokine receptors. Cytokine-dependent dimerization is conveyed across the cell membrane to drive JAK dimerization, trans-phosphorylation, and activation.
Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, Caleb R. Glassman, Naotaka Tsutsumi, Stevan R. Hubbard, K. Christopher Garcia   +6 more
doaj   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source